The absence of specific Ad-EV markers also limits the targeting of these particles for clinical purposes, especially when considering that current markers have been described to be modulated under pathological conditions (i.e., FABP4 and obesity) or are a currently a matter of concern due to their potential co-isolation as non-EV structures (i.e., adiponectin or PLIN-1) [43]. This evidence concerns the gene FABP4 and Obesity.